EB-203 / EyebioKorea - LARVOL DELTA

Evaluation of EB-203 as a potential treatment for non-proliferative diabetic retinopathy using a zebrafish model. (PubMed, Biomed Pharmacother) - "EB-203 was found to reduce microvascular leakage changes, edema features, and inflammatory responses associated with NPDR-like phenotypes, suggesting its potential to limit progression toward PDR conditions. Overall, EB-203 demonstrated significant efficacy in improving NPDR like retinal pathology in zebrafish and holds promise as a potential therapeutic candidate for DR."

Journal • Diabetes • Diabetic Retinopathy • Inflammation • Retinal Disorders

EB-203-201: Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - P2 | N=50 | Recruiting | Sponsor: EyebioKorea, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

EB-203-201: Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - P2 | N=50 | Not yet recruiting | Sponsor: EyebioKorea, Inc.

New P2 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Safety, Tolerability and Pharmacokinetics of EB-203 Eye Drops in Healthy Volunteers (clinicaltrials.gov) - P1 | N=28 | Completed | Sponsor: EyebioKorea, Inc. | Recruiting ➔ Completed | Trial completion date: May 2023 ➔ Oct 2022

Trial completion • Trial completion date

Safety, Tolerability and Pharmacokinetics of EB-203 Eye Drops in Healthy Volunteers (clinicaltrials.gov) - P1 | N=28 | Recruiting | Sponsor: EyebioKorea, Inc.

New P1 trial